Pulmonx Q2 revenue $14.0M (+14% YoY); net loss $14.6M; reaffirms FY outlook

Pulmonx Corp

2022-Q2 EPS reported -$0.83 revenue$24,735,000

Revenue $14.0M, up 14% YoY (19% constant currency); U.S. revenue $8.6M (+31%).
Net loss $14.6M ($0.40/share) vs $13.0M ($0.36/share) in Q2 2021.
Gross margin improved to 75% from 74% due to production efficiencies.
Added 18 new U.S. treatment centers (total 248); cash $166.8M.
FY2022 revenue guidance reaffirmed $55M-$60M; operating expenses $100M-$105M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.